Augusta University

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Schizophrenia

  NCT07410507· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

  NCT07187973· Phase 1· Disc Medicine, Inc· Source

• Enrolling by invitation

  Assessing Obesity Related Risk Factors in Adult Population: A Genetic and Behavioral Study

  NCT07341841· Augusta University· Source

• Recruiting

  Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

  NCT06658730· W.L.Gore & Associates· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Lifestyle Intervention for Healthy Change

  NCT05956574· Augusta University· Source

• Recruiting

  A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

  NCT06680830· Phase 2· Neuron23 Inc.· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Recruiting

  A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

  NCT06481592· Phase 2· Iovance Biotherapeutics, Inc.· Source

• Recruiting

  A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  NCT06586957· Phase 1· NiKang Therapeutics, Inc.· Source

• Recruiting

  A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

  NCT06504589· Nicole Hamblett· Source

• Recruiting

  A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

  NCT06559150· Phase 2· Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Recruiting

  Mobile App Logging for Diabetes in Pregnancy

  NCT06005987· Carolyn Zahler-Miller· Source

• Active, not recruiting

  A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06132893· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

  NCT06132958· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

  NCT05598333· Phase 2· AskBio Inc· Source

• Recruiting

  Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

  NCT06385886· RTI International· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

  NCT05648500· Phase 3· Viatris Innovation GmbH· Source

• Active, not recruiting

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Biogen· Source

• Active, not recruiting

  A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

  NCT05348733· Bayer· Source

• Recruiting

  Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

  NCT05156398· Phase 3· Pfizer· Source

• Recruiting

  A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  NCT05006716· Phase 1/2· BeOne Medicines· Source

• Active, not recruiting

  Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

  NCT04747613· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Automated Imaging Differentiation of Parkinsonism

  NCT05913687· University of Florida· Source

• Active, not recruiting

  Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

  NCT04229979· Phase 3· Sellas Life Sciences Group· Source

• Active, not recruiting

  Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

  NCT04539964· Phase 3· SetPoint Medical Corporation· Source

• Active, not recruiting

  HEALEY ALS Platform Trial - Master Protocol

  NCT04297683· Phase 2/3· Merit E. Cudkowicz, MD· Source

• Active, not recruiting

  Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

  NCT04057898· Phase 2/3· MediciNova· Source

• Active, not recruiting

  Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

  NCT04416984· Phase 1/2· Allogene Therapeutics· Source

• Active, not recruiting

  Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

  NCT04146051· Phase 2· Cartesian Therapeutics· Source

• Recruiting

  A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

  NCT03887715· LivaNova· Source

• Active, not recruiting

  A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  NCT03522246· Phase 3· pharmaand GmbH· Source

• Active, not recruiting

  AMPLATZER PFO Occluder Post Approval Study

  NCT03309332· Abbott Medical Devices· Source

• Active, not recruiting

  A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

  NCT03336333· Phase 3· BeiGene· Source

• Recruiting

  American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

  NCT02674100· University of Louisville· Source

• Active, not recruiting

  Endothelin Receptor Function and Acute Stress

  NCT02116335· Augusta University· Source

• Recruiting

  Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  NCT01245179· Phase 1· Abdullah Kutlar· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Sickle cell disease3 recruiting
• Bronchiectasis2 recruiting
• Cystic fibrosis2 recruiting
• Endometrial cancer2 recruiting
• Obesity2 recruiting
• Aortic aneurysm1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Depression1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Lung cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Migraine1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Parkinson disease1 recruiting
• Schizophrenia1 recruiting
• Thalassaemia1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

  NCT06016088· Phase 1/2· Respirion Pharmaceuticals Pty Ltd· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  Early Parkinson's Disease Monotherapy With CVN424

  NCT06006247· Phase 2· Cerevance Beta, Inc.· Source

• Completed

  Does EVOO Induce Gene and Metabolic Changes in Healthy Subjects

  NCT05929924· Augusta University· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

  NCT05483907· Phase 2· Bridge Biotherapeutics, Inc.· Source

• Completed

  A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

  NCT05695950· Phase 2· Lakefront Biotherapeutics NV· Source

• Completed

  Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

  NCT05605964· Phase 3· Sumitomo Pharma America, Inc.· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Recruiting

  Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT05327114· Phase 2/3· Janssen Research & Development, LLC· Source

• Completed

  A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

  NCT05425056· Phase 3· Vascular Therapies, Inc.· Source

• Completed

  Thoracic Neuromodulation for Diabetic Gastroparesis

  NCT05273788· Medical University of South Carolina· Source

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

  NCT05379634· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

  NCT04930445· Pfizer· Source

• Completed

  A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

  NCT05053139· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

  NCT04683848· Phase 2· Tanabe Pharma America, Inc.· Source

• Completed

  CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

  NCT04860830· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

  NCT04951622· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Incyte Corporation· Source

• Terminated

  The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

  NCT04753385· LivaNova· Source

• Completed

  LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

  NCT04790344· Boston Scientific Corporation· Source

• Completed

  Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

  NCT04266197· Phase 2· Respira Therapeutics, Inc.· Source

• Completed

  REal-World Analyses of Stroke - Thrombus Occlusion REtrieval

  NCT04451525· Microvention-Terumo, Inc.· Source

• Completed

  A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

  NCT04300647· Phase 2· Hoffmann-La Roche· Source

• Completed

  Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

  NCT04223791· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Trial of Parkinson's And Zoledronic Acid

  NCT03924414· Phase 4· California Pacific Medical Center Research Institute· Source

• Completed

  A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function

  NCT04038047· Nicole Hamblett· Source

• Completed

  Sildenafil Exercise: Role of PDE5 Inhibition

  NCT04039087· Phase 2/3· National Jewish Health· Source

• Terminated

  Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

  NCT02530034· Phase 1· M.D. Anderson Cancer Center· Source

• Completed

  Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

  NCT03578367· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

  NCT03734016· Phase 3· BeiGene· Source

• Completed

  Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

  NCT03526354· Phase 4· University of Massachusetts, Worcester· Source

• Completed

  Estrogen and Diabetes

  NCT03436992· Augusta University· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.

  NCT01467427· Phase 3· Novo Nordisk A/S· Source

• Completed

  TEDDY - The Environmental Determinants of Diabetes in the Young

  NCT00279318· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Acute myeloid leukaemia22 works · 3 trials
• Cystic fibrosis21 works · 7 trials
• Endometrial cancer15 works · 3 trials
• Chronic myeloid leukaemia14 works · 2 trials
• Aortic aneurysm14 works · 1 trial
• Sickle cell disease12 works · 5 trials
• Peripheral artery disease11 works · 1 trial
• Hidradenitis suppurativa6 works · 0 trials
• Narcolepsy5 works · 0 trials
• Vitiligo5 works · 0 trials
• Polycystic kidney disease3 works · 0 trials